Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00584818 · ClinicalTrials.gov registry record · Phase 2
Dose Finding Study of PB127 Ultrasound Contrast Agent in Healthy Volunteers and Patients With Coronary Artery Disease
A Phase 2 study, sponsored by Point Biomedical.
- Completed
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
NCT00584818 is a Phase 2 study that has completed, run by Point Biomedical. The registered enrollment target is 205 participants.
The verdict
NCT00584818, a Phase 2 study, has completed, sponsored by Point Biomedical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the dose of PB127 for detection and/or exclusion of coronary artery disease when used with cardiac ultrasound. This study also evaluates the safety of PB127.
Interventions
- DRUG PB127 for Injectable Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00584818
The ClinicalTrials.gov registry entry for NCT00584818 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Point Biomedical, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PB127 for Injectable Suspension is the first listed.
NCT00584818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00584818 about?
NCT00584818 is a clinical study titled "Dose Finding Study of PB127 Ultrasound Contrast Agent in Healthy Volunteers and Patients With Coronary Artery Disease". The purpose of this study is to determine the dose of PB127 for detection and/or exclusion of coronary artery disease when used with cardiac ultrasound. This study also evaluates the safety of PB127.
What is the current status of trial NCT00584818?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2006-11. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00584818?
The interventions under investigation include: PB127 for Injectable Suspension (DRUG).
Who is sponsoring clinical trial NCT00584818?
This trial is sponsored by Point Biomedical, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.